KIORA PHARMACEUTICALS INC
KPRXNasdaq
$2.63
↑ +3.1%Jul 17 close · end-of-day
Price
1Y↓ -16.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$11.0M
Enterprise Value
-$2.9M
P/E
—
P/S
—
P/B
0.8
EV/EBITDA
—
PEG
—
FCF Yield
-95.9%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$235,839.00
Free Cash Flow (TTM)
-$10.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-1.7%
ROIC
-16445.5%
Debt / Equity
—
Net Cash
$13.9M
Return 1Y
-16.5%
Company profile
Kiora Pharmaceuticals, Inc. develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
- CEO
- Brian M. Strem
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- California
- Website
- kiorapharma.com
Management & directors
- Strem Brian M.President and CEO
- Tosca MelissaCFO
- Daniels Eric JosephChief Development Officer
Roles derived from SEC Form 4 filings.
Earnings
KPRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.58↑ +11.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $12,059.00 | $0.00 | — | $0.00 | $16.0M | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.9M | -$14.2M | -$12.3M | -$12.6M | $4.5M | -$12.8M |
| Net income | -$6.9M | -$13.8M | -$13.6M | -$12,514.00 | $3,595.00 | -$10,835.00 |
| Diluted EPS | -$1.49 | -$57.12 | -$18.55 | -$24.25 | $0.87 | -$2.64 |
| Operating cash flow | -$7.3M | -$10.7M | -$10.4M | -$9.6M | $8.6M | -$10.0M |
| Free cash flow | -$7.3M | -$10.7M | -$10.4M | -$9.6M | $8.6M | -$10.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -56960.5% | — | — | — | 28.2% | — |
| Net margin | -56901.7% | — | — | — | 0.0% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20,000.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.5M | -$3.6M | -$2.6M | -$2.3M | -$2.4M | -$794,437.00 | -$7.3M | -$2.5M |
| Net income | -$2.2M | -$3.4M | -$7.8M | -$2.2M | -$2.2M | $26,806.00 | $4.3M | -$2.4M |
| Diluted EPS | -$0.53 | -$0.81 | -$1.25 | -$0.52 | -$0.54 | $0.01 | -$1.59 | -$0.58 |
| Operating cash flow | -$3.7M | $920,057.00 | -$2.3M | -$2.7M | -$3.8M | -$1.3M | -$2.2M | -$3.2M |
| Free cash flow | — | $920,057.00 | — | -$2.7M | -$3.8M | -$1.3M | -$2.3M | -$3.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -12724.4% | — | — | — | — | — | — | — |
| Net margin | -11108.2% | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Strem Brian M.· President and CEO | Tax withholding | 1,869 | $2.66 | $4,971.54 | filing |
| 2026-07-01 | Tosca Melissa· CFO | Tax withholding | 911 | $2.66 | $2,423.26 | filing |
| 2026-04-01 | Strem Brian M.· President and CEO | Tax withholding | 1,906 | $1.95 | $3,716.70 | filing |
| 2026-04-01 | Tosca Melissa· CFO | Tax withholding | 929 | $1.95 | $1,811.55 | filing |
| 2026-04-01 | Daniels Eric Joseph· Chief Development Officer | Tax withholding | 929 | $1.95 | $1,811.55 | filing |
| 2026-03-06 | Daniels Eric Joseph· Chief Development Officer | Award | 6,533 | $0.00 | $0.00 | filing |
| 2026-03-06 | Strem Brian M.· President and CEO | Award | 16,733 | $0.00 | $0.00 | filing |
| 2026-03-06 | Tosca Melissa· CFO | Award | 6,533 | $0.00 | $0.00 | filing |
| 2026-03-03 | Daniels Eric Joseph· Chief Development Officer | Tax withholding | 238 | $2.02 | $480.76 | filing |
| 2026-03-03 | Strem Brian M.· President and CEO | Tax withholding | 238 | $2.02 | $480.76 | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.